RNA Analytical/Quality Videos

  1. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

    Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

  2. How "Successful" Are Our mRNA-LNP Outsourcing Partnerships Today? 2/10/2025

    In this snippet, panelist Alex Aust (with the help of several live attendee commenters) tackles a particularly tricky question: Are our outsourcing partnerships producing high quality products today, and what are the most common root causes of batch failures?

  3. Taming dsRNA Via Innovation In The Supply Chain 10/15/2025

    Here, Ethris’ Christan Dohmen and Tune Therapeutics’ Stu Sundseth share their take on the most meaningful strategies for reducing dsRNA production. But this discussion also probes a deeper question: Is dsRNA still the most relevant impurity the industry should be chasing, or should focus shift to other contaminants? 

  4. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

  5. The "Golden Idea Of The Platform" & Its Role In mRNA PD 8/22/2024

    Explore how early-stage companies can implement design space and analytical principles that will help us determine the biggest differences between constructs and how close we may be to a true “platform process.”

  6. mRNA/saRNA Manufacturing: Accelerate The Path To Clinic 3/22/2021

    Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.

  7. Is QbD Actually Possible In mRNA Development Today? 8/22/2024

    As the panelists of this Advancing RNA LIVE discussion argue, there are several big limitations we face in implementing QBD today for RNA development.

  8. Select An Ion-Pairing Agent For Impurity Analysis Of Oligonucleotides 5/4/2022

    Learn about method development considerations when selecting an appropriate ion-pairing agent and impurity analysis of dye-conjugated oligonucleotides.

  9. Streamline Your mRNA Purification Steps 3/4/2025

    Ensure your mRNA's stability and effectiveness post-transcription with advanced filtration and chromatography techniques to enhance purity and recovery, which delivers high-quality mRNA for superior therapeutics and vaccines.

  10. The Conjugation Conundrum: The Realities Of Conjugated LNP Manufacturing 2/24/2026

    In this Advancing RNA Live clip, CMC Consultant Sujit Jain explains the numerous ways that adding targeting ligands “stress tests” the standard LNP manufacturing platform, as well as outlines which capabilities are most important for companies to consider when selecting an outsourcing partner for their active delivery strategies.